Market closedNon-fractional
Kronos Bio/KRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Ticker
KRON
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Mateo, United States
Employees
61
Website
www.kronosbio.com
Kronos Bio Metrics
BasicAdvanced
$69M
Market cap
-
P/E ratio
-$2.00
EPS
1.85
Beta
-
Dividend rate
Price and volume
Market cap
$69M
Beta
1.85
Financial strength
Current ratio
8.321
Quick ratio
7.986
Long term debt to equity
17.856
Total debt to equity
20.059
Interest coverage (TTM)
-492.84%
Management effectiveness
Return on assets (TTM)
-28.58%
Return on equity (TTM)
-64.20%
Valuation
Price to revenue (TTM)
8.843
Price to book
0.51
Price to tangible book (TTM)
0.51
Price to free cash flow (TTM)
-0.691
Growth
Revenue change (TTM)
521.38%
Earnings per share change (TTM)
-8.44%
3-year earnings per share growth
-19.24%
What the Analysts think about Kronos Bio
Analyst Ratings
Majority rating from 3 analysts.
Kronos Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.5M
13.64%
Net income
-$30M
18.18%
Profit margin
-1,196.00%
4.00%
Kronos Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.52
-$0.54
-$0.43
-$0.50
-
Expected
-$0.46
-$0.51
-$0.53
-$0.42
-$0.34
Surprise
13.04%
5.37%
-18.10%
18.34%
-
Kronos Bio News
AllArticlesVideos
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·1 month ago
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
GlobeNewsWire·1 month ago
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kronos Bio stock?
Kronos Bio (KRON) has a market cap of $69M as of July 06, 2024.
What is the P/E ratio for Kronos Bio stock?
The price to earnings (P/E) ratio for Kronos Bio (KRON) stock is 0 as of July 06, 2024.
Does Kronos Bio stock pay dividends?
No, Kronos Bio (KRON) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Kronos Bio dividend payment date?
Kronos Bio (KRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Kronos Bio?
Kronos Bio (KRON) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Kronos Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.